COGT
- Cogent Biosciences, Inc.
()
Overview
Company Summary
Cogent Biosciences, Inc. (COGT) is a biotechnology company focused on developing precision medicines for patients with genetically defined diseases. The company's main objective is to address unmet medical needs by utilizing its expertise in precision medicine and targeted therapies.
Cogent Biosciences primarily focuses on developing therapies for fibrosis-related diseases, such as idiopathic pulmonary fibrosis (IPF) and other forms of fibrosis where there is a high unmet need and limited treatment options available. IPF is a chronic and progressive lung disease characterized by scarring of the lung tissue, leading to difficulty in breathing and ultimately respiratory failure.
The company's approach involves leveraging its proprietary genomic screening platform, known as the Disease-relevant Allele Discovery Platform (DReAD), to identify genetic mutations associated with fibrosis. By analyzing patient samples and genetic data, Cogent Biosciences aims to understand the underlying genetic drivers of fibrosis and develop targeted therapies to address these specific mutations.
COGT is currently advancing its lead drug candidate, CBP-201, which is an investigational oral small molecule inhibitor designed to target the underlying genetic causes of fibrosis. The company aims to develop CBP-201 as a potential treatment for patients with IPF and other fibrotic diseases associated with known genetic mutations.
Overall, Cogent Biosciences is dedicated to developing precision medicines that have the potential to transform the lives of patients suffering from fibrosis-related diseases. The company's focus on understanding the genetic basis of these conditions and developing targeted therapies sets it apart in the field of biotechnology.